COPD Collaboration Exploit the COPD Foundation strategic alliance to pursue co-development or licensing of inhaled therapies for COPD and other chronic lung diseases, accelerating clinical programs and reducing time to patient access. Target opportunities with providers, patient advocacy groups, and reimbursement bodies to demonstrate value.

R&D Acceleration Position DevPro Biopharma as a boutique CRO/accelerator for early to mid-stage programs, offering rapid study design, protocol development, CMC support, regulatory strategy, and data management to shorten development timelines and improve success rates for partner programs.

Geographic Edge Leverage New Jersey base to connect with regional investigators, contract manufacturers, and clinical trial networks, enabling cost-efficient multi-site COPD trials and faster site activation and patient recruitment in the Northeast.

Lung Disease Expansion Explore expansion into related pulmonary indications and device-enabled therapies, offering end-to-end development including formulation, device integration, preclinical and translational support, and pharmacovigilance to broaden the addressable market.

Growth Partnerships Target mid- to large-cap pharma partners seeking speed-to-market and risk-sharing arrangements, proposing milestone-based deals and ongoing development services to become a preferred outsourced R&D partner for lung disease programs.